|
|
|
|
Vol. 56, Issue 3, 581-587, September 1999
National Cancer Institute, Bethesda, Maryland (A.S., P.M.B.); and Neurogen Corp., Branford, Connecticut (L.L.A., J.E.K., D.N.C.)
| |
Summary |
|---|
|
|
|---|
[3H]Resiniferatoxin (RTX) binding and calcium uptake by rat dorsal root ganglion (DRG) neurons show distinct structure-activity relations, suggestive of independent vanilloid receptor (VR) subtypes. We have now characterized ligand binding to rat VR1 expressed in human embryonic kidney (HEK293) and Chinese hamster ovary (CHO) cells and compared the structure-activity relations with those for calcium mobilization. Human embryonic kidney cells (HEK293/VR1 cells) and Chinese hamster ovary cells transfected with VR1 (CHO/VR1 cells) bound [3H]RTX with affinities of 84 and 103 pM, respectively, and positive cooperativity (Hill numbers were 2.1 and 1.8). These parameters are similar to those determined with rat DRG membranes expressing native VRs (a Kd of 70 pM and a Hill number of 1.7). The typical vanilloid agonists olvanil and capsaicin inhibited [3H]RTX binding to HEK293/VR1 cells with Ki values of 0.4 and 4.0 µM, respectively. The corresponding values in DRG membranes were 0.3 and 2.5 µM. HEK293/VR1 cells and DRG membranes also recognized the novel vanilloids isovelleral and scutigeral with similar Ki values (18 and 20 µM in HEK293/VR1 cells; 24 and 21 µM in DRGs). The competitive vanilloid receptor antagonist capsazepine inhibited [3H]RTX binding to HEK293/VR1 cells with a Ki value of 6.2 µM and binding to DRG membranes with a Ki value of 8.6 µM. RTX and capsaicin induced calcium mobilization in HEK293/VR1 cells with EC50 values of 4.1 and 82 nM, respectively. Thus, the relative potencies of RTX (more potent for binding) and capsaicin (more potent for calcium mobilization) are similar in DRG neurons and cells transfected with VR1. We conclude that VR1 can account for both the ligand binding and calcium uptake observed in rat DRG neurons.
| |
Introduction |
|---|
|
|
|---|
The
term vanilloid receptor was coined to describe the neuronal membrane
recognition site for capsaicin and related irritant compounds (Szallasi
and Blumberg, 1990a
, 1999
). It was postulated that the VR is a
nonselective cation channel with a preference for calcium (Bevan et
al., 1987
; Bevan and Szolcsányi, 1990
). Consequently, a
45Ca2+-uptake assay
performed with intact rat dorsal root ganglion (DRG) neurons has been
used extensively to characterize structure-activity relations for
vanilloids (Wood et al., 1988
; Walpole and Wrigglesworth, 1993
;
Ács et al., 1996
). In 1989, resiniferatoxin (RTX) was recognized as an ultrapotent vanilloid (Szallasi and Blumberg, 1989
). Specific binding of [3H]RTX provided the first
unequivocal proof for the existence of a vanilloid receptor (Szallasi
and Blumberg, 1990b
) and has furnished a new, biochemical tool to study
vanilloid receptor pharmacology (Szallasi and Blumberg, 1990a
, 1999
;
Szallasi, 1994
).
If binding and calcium uptake were mediated by the same receptor, a
logical prediction would be that these two responses should display
similar structure-activity relations. With regard to DRG neurons
expressing native vanilloid receptors, this is clearly not the case:
structure-activity analysis of different vanilloid derivatives revealed
that the various compounds have distinct potencies for receptor binding
and inducing 45Ca2+-uptake
(Ács et al., 1995
, 1996
; Walpole et al., 1996
). One extreme is
RTX, which is approximately 25-fold more potent for binding (Kd = 40 pM) than for inducing calcium
uptake (EC50 = 1.0 nM) (Ács et al., 1996
).
The other extreme is capsaicin, which evokes calcium influx with an
EC50 of 270 nM but inhibits
[3H]RTX binding with a 10-fold lower affinity
of 3 µM (Ács et al., 1996
). One model to account for the above
discrepancies in vanilloid structure-activity relations was that RTX
binding and calcium uptake detected two distinct classes of vanilloid
receptors (Szallasi and Blumberg, 1996
; Bíró et al.,
1997
). These putative receptors were referred to as R-type
(preferentially labeled by RTX) and C-type (displaying a higher potency
for capsaicin) vanilloid receptors, respectively. This model was
further supported by the identification of non-neuronal cell lines that
responded to vanilloids with calcium uptake (implying the presence of
C-type vanilloid receptors) but lacked detectable specific RTX binding
sites (Bíró et al., 1998a
,b
). An alternative model was
based on the assumption that the vanilloid binding site may be
within or at the inner face of the cell membrane (Walpole and
Wrigglesworth, 1993
). If this is so, then the calcium uptake assay may
be subject to access constraints due to differences in cell membrane
penetration, leading to distinct and independent structure-activity
profiles from binding affinities for the compounds.
A functional rat vanilloid receptor, termed VR1, activated not
only by vanilloids but also by noxious heat and low pH, has recently
been cloned (Caterina et al., 1997
; Tominaga et al., 1998
). As
predicted, this VR1 is a nonselective cation channel with a preference
for calcium (Caterina et al., 1997
). In Xenopus oocytes
expressing VR1, vanilloids evoke inward currents, with RTX being
approximately 20-fold more potent (EC50 = 39 nM)
than capsaicin (EC50 = 710 nM) (Caterina et al.,
1997
). In VR1-transfected mammalian [human embryonic kidney (HEK293)]
cells, capsaicin induces whole-cell currents with a potency of 110 nM
(Tominaga et al., 1998
). Taken together, these results suggest that VR1
corresponds to the site in DRG neurons that mediates calcium uptake.
To evaluate the hypothesis that binding and calcium uptake detect two
distinct classes of vanilloid receptors in DRG neurons (Szallasi and
Blumberg, 1996
; Bíró et al., 1997
), in the present study
we have transfected mammalian [HEK293 and Chinese hamster ovary
(CHO)] cells with a cDNA encoding the rat VR1 and used these cells for
RTX binding and calcium mobilization experiments, respectively. In the
binding experiments, both typical (capsaicin and olvanil) and novel
(isovelleral and scutigeral) vanilloids were included, as well as the
competitive vanilloid receptor antagonist capsazepine. Vanilloid
binding to HEK293/VR1 cells was compared to that measured in rat DRG
neurons expressing native vanilloid receptors. Calcium mobilization in
HEK293/VR1 or CHO/VR1 cells was determined in response to RTX, olvanil,
and capsaicin, by using a calcium-activated fluorescent dye method. In
addition, capsaicin-induced calcium mobilization in the VR1-transfected
cells was measured in the presence of capsazepine or the so-called
functional vanilloid receptor antagonist, ruthenium red. Agonist and
antagonist potencies determined in the calcium mobilization assays with
HEK293/VR1 or CHO/VR1 cells were compared with values measured
previously in this laboratory for vanilloid-induced
45Ca2+-uptake by intact rat
DRG neurons.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials. [3H]RTX (37 Ci/mmol) was synthesized by the Chemical Synthesis and Analysis Laboratory, National Cancer Institute-Frederick Cancer Research and Development Center (Frederick, MD). Nonradioactive RTX was purchased from Alexis Corp. (San Diego, CA), and capsazepine was from Research Biochemicals, Inc. (Natick, MA). Olvanil was a generous gift from Procter & Gamble Corp. (Cincinnati, OH). Isovelleral and scutigeral were donated by Olov Sterner (Lund University, Lund, Sweden). All the other chemicals used were purchased from Sigma (St. Louis, MO) unless indicated otherwise.
Molecular Biology.
A cDNA encoding the vanilloid receptor
VR1 was cloned from rat DRG total RNA by reverse
transcription-polymerase chain reaction, by using primers based on the
published nucleotide sequence (Caterina et al., 1997
). A 2.7-kilobase
cDNA was isolated, and the nucleotide sequence was verified to be
identical with the published sequence. This cDNA was subcloned into
pcDNA3.1 (Invitrogen, Carlsbad, CA) and pUHG102-3 (Clontech, Palo
Alto, CA) for recombinant expression in mammalian cells.
Cell Culture.
The pcDNA3.1 VR1 plasmid was transfected into
HEK293 cells by standard methods. These transfected cells were selected
for 2 weeks in media containing G418 (400 µg/ml) and then maintained as a pool of stably transfected cells. The pUHG102 VR1 plasmid was
transfected into CHO cells containing the pTet Off Regulator plasmid
(Clontech). In these cells, expression of the pUHG plasmid is repressed
in the presence of tetracycline but is induced upon removal of the
antibiotic. Stable clones were isolated in culture medium containing
puromycin (10 µg/ml) and maintained in medium supplemented with
tetracycline (1 µg/ml). Cells utilized for assays were grown in
culture medium without antibiotic for 48 to 72 h before use. For
radioligand binding experiments, cells were seeded in T175 cell culture
flasks in media without antibiotics and grown to approximately 90%
confluency. The flasks were then washed with PBS and harvested in PBS
containing 5 mM EDTA. The cells were pelleted by gentle centrifugation
and stored at
80°C until assayed. For calcium mobilization assays,
cells were seeded into 96-well plates and grown to 70 to 90% confluency.
Membrane Preparations.
Female Sprague-Dawley rats weighing
200 to 250 g were euthanized under CO2
anesthesia. The spinal columns were opened and DRGs were collected from
all levels into ice-cold physiological saline. DRGs were disrupted with
the aid of a tissue homogenizer in an ice-cold buffer (pH 7.4)
containing 5 mM KCl, 5.8 mM NaCl, 0.75 mM CaCl2,
2 mM MgCl2, 320 mM sucrose, and 10 mM HEPES.
Tissue homogenates were first centrifuged for 10 min at
1,000g (4°C) to remove the nuclear fraction and debris,
and then the supernatant from the first centrifugation was again
centrifuged for 30 min at 35,000g (4°C) to obtain a
partially purified membrane fraction. Membranes resuspended in the
homogenization buffer were stored at
80°C until assayed.
Radioligand Binding.
Binding studies with
[3H]RTX were carried out according to a
published protocol (Szallasi et al., 1992
) in which nonspecific RTX
binding is reduced by adding bovine
1-acid
glycoprotein (100 µg per tube) after the binding reaction has been
terminated. Binding assay mixtures were set up on ice and contained
[3H]RTX, nonradioactive ligands, 0.25 mg/ml
BSA (Cohn fraction V), and either 5 × 104 to 1 × 105
VR1-transfected cells or 40 µg of DRG membrane protein. The final volume was adjusted to 500 (competition binding assays) or 1000 µl
(saturation binding assays) with the buffer described above. Nonspecific binding was defined as that occurring in the presence of 1 µM nonradioactive RTX. For saturation binding,
[3H]RTX was added in the concentration range of
7 to 1000 pM, with one to two dilutions. Competition binding assays
were performed in the presence of 30 (for DRG membranes) or 60 pM (for
VR1-transfected cells) [3H]RTX and various
concentrations of competing ligands. The binding reaction was initiated
by transferring the assay mixtures into a 37°C water bath and was
terminated after a 60-min incubation period by cooling the tubes on
ice. Membrane-bound RTX was separated from the free as well as the
1-acid glycoprotein-bound RTX by pelleting the
membranes in a Beckman 12 benchtop centrifuge (15 min, maximal
velocity), and the radioactivity was determined by scintillation
counting. Equilibrium binding parameters were determined by fitting the
Hill equation to the measured values with the aid of the computer
program FitP (Biosoft, Ferguson, MO) as described previously (Szallasi
et al., 1993
).
Calcium Mobilization Assays. VR1-transfected cells were seeded into 96-well plates and grown to 70 to 90% confluency. The cells were then washed once with Krebs-Ringer HEPES buffer (25 mM HEPES, 5 mM KCl, 0.96 mM NaH2PO4, 1 mM MgSO4, 2 mM CaCl2, 5 mM glucose, 1 mM probenecid, pH 7.4) and incubated for 1 to 2 h in the above buffer supplemented with the calcium-sensitive fluorescent dye Fluo3-AM (2.5-10 µg/ml; Teflabs, Austin, TX) at 37°C in an environment containing 5% CO2. In some experiments (as indicated in Results), the Krebs-Ringer HEPES buffer was also supplemented with 1 mg/ml BSA (Cohn fraction V). The wells were then washed twice with Krebs-Ringer HEPES buffer. Addition of agonist (olvanil, capsaicin, or RTX) to the wells resulted in concentration-dependent changes in intracellular calcium levels and subsequent activation of Fluo3 fluorescence. Fluoroskan Ascent (Labsystems, Franklin, MA) or FLIPR (Molecular Devices, Sunnyvale, CA) instruments were used to monitor changes in fluorescence for up to 180 s and to determine the maximum fluorescence signal. Similarly, varying concentrations of the antagonists ruthenium red and capsazepine were added to cells concurrently with agonist (25-50 nM capsaicin). For the capsaicin- and olvanil-induced calcium responses, data obtained between 30 and 60 s after agonist application were used to generate the EC50 values. Because the time course of RTX-evoked responses was more prolonged than that of capsaicin (see Results), data obtained between 120 and 180 s were used to determine EC50 values. Kaleidagraph software (Synergy Software, Reading, PA) was utilized to fit the data to the equation y = a · (1/(1 + (b/x)c)) to determine the EC50 for the response. In this equation, y is the maximum fluorescence signal, x is the concentration of the agonist or antagonist, a is the Emax, b corresponds to the EC50 or IC50 value, and, finally, c is the Hill coefficient.
| |
Results |
|---|
|
|
|---|
VR1-Transfected Mammalian Cells (HEK293 and CHO) and Rat DRG
Membranes Expressing Native Vanilloid Receptors Bind
[3H]RTX with Similar Parameters.
The association of
[3H]RTX (60 pM) to VR1 expressed on HEK293
cells was rapid: within 10 min, the specific binding attained approximately 90% of its peak value, and it then remained on a plateau
between 20 and 60 min of incubation (a single experiment; data
not shown). When dissociation was initiated after a 60-min association,
it could be fitted to a first order decay curve, yielding a
dissociation constant of 0.12 ± 0.02 min
1
(two determinations; data not shown). Based on these preliminary experiments, an incubation period of 60 min was selected for the equilibrium binding studies.
|
|
Vanilloid Agonists and the Antagonist Capsazepine Inhibit
[3H]RTX Binding by VR1-Transfected Mammalian Cells and
Rat DRG Membranes, Respectively, with Similar Affinities.
For the
pharmacological characterization of the RTX recognition site on rat VR1
expressed in HEK293 cells, four agonists (olvanil, capsaicin,
isovelleral, and scutigeral) and an antagonist (capsazepine) were
selected (Fig. 3). Apparent
Ki values of the agonists were: olvanil,
0.4 ± 0.1 µM (n = 4); capsaicin, 4.0 ± 0.8 µM (n = 6); isovelleral, 20 ± 4 µM
(n = 3); and scutigeral, 18 ± 3 µM
(n = 3; all values are mean ± S.E.M.). The
competitive antagonist capsazepine inhibited
[3H]RTX binding with a
Ki of 6.2 ± 0.7 µM (mean ± S.E.M.; five experiments). These Ki values
are similar to those determined with rat DRG membranes: olvanil,
0.3 ± 0.1 µM; capsaicin, 2.5 ± 1.1 µM; isovelleral,
24 ± 4 µM; scutigeral, 21 ± 3 µM; and capsazepine,
8.6 ± 3.5 µM (mean ± S.E.M.; three experiments; Table
1). The binding affinities of olvanil,
capsaicin, and capsazepine were also determined with CHO/VR1 cells:
Ki values were 0.26 ± 0.5, 1.7 ± 0.4, and 6.6 ± 1.4 µM, respectively (mean ± range; two
determinations; Table 1).
|
|
Characterization of VR1-Transfected Mammalian Cells in the Calcium
Mobilization Assay by Using Various Vanilloid Compounds.
Capsaicin
induced calcium mobilization in HEK293/VR1 cells and CHO/VR1 cells with
EC50 values of 82 ± 17 nM (mean ± S.E.M.; n = 4) and 38 ± 13 nM (mean ± S.E.M.; n = 5), respectively. RTX was more than an
order of magnitude more potent in both cell lines; EC50 values were 4.1 ± 1.3 nM in HEK293/VR1
cells (mean ± S.E.M.; n = 5), and 1.4 ± 0.8 nM in CHO/VR1 cells (mean ± S.E.M.; n = 4).
Capsaicin and RTX differed not only in potency in the calcium mobilization assay, but also in the kinetics of the response (Fig. 4). Capsaicin administration resulted in
a rapid response (Fig. 4A). By contrast, RTX-evoked calcium
mobilization became detectable after an initial delay only (compare
Fig. 4, A and B). By using 30 nM capsaicin, a concentration close to
the EC50 in CHO/VR1 cells, the calcium
mobilization response achieved its peak value within 1 min and then
started to decline, suggesting the development of tachyphylaxis, or due
to some other aspect of channel gating (Fig. 4A). By contrast, calcium
mobilization in response to 1 nM RTX increased steadily over a 3-min
period after challenge, approaching the maximal response evoked by 100 nM RTX (Fig. 4B). This difference between the kinetics of capsaicin-
and RTX-induced responses, however, did disappear when high,
supramaximal doses were used (30 µM capsaicin or 100 nM RTX; compare
Fig. 4, A and B). Olvanil evoked the calcium response in CHO/VR1 cells
with a potency of 22 ± 6 nM (mean ± S.E.M.;
n = 7). The time course of the olvanil-induced calcium
mobilization response was similar to that by capsaicin (not shown).
Administering 25 nM capsaicin to evoke calcium mobilization,
capsazepine inhibited this response with an IC50
value of 2.4 ± 0.5 µM (mean ± S.E.M.; n = 6). However, this value was shifted by almost an order of magnitude in
the presence of 1 mg/ml BSA to yield an IC50 of
0.33 ± 0.03 µM (mean ± S.E.M.; n = 5).
From the concentration of agonist (25 nM capsaicin) and the
IC50 for antagonist, the following capsazepine
Ki values can be calculated: 140 nM in the
presence and 2400 nM in the absence of BSA, respectively (Table 1). For
the other vanilloids tested in this study, the presence or absence of
BSA had no detectable influence on the calcium mobilization potency.
With an IC50 of 210 ± 30 nM (mean ± S.E.M.; n = 7), the functional antagonist ruthenium red
was approximately 1.5-fold more potent than capsazepine (IC50 = 330 nM in the presence of BSA) to prevent
calcium mobilization by capsaicin.
|
| |
Discussion |
|---|
|
|
|---|
[3H]RTX binding and
45Ca2+-uptake are standard
assays to characterize the pharmacology of native vanilloid receptors
on primary sensory neurons. Structure-activity analysis of a number of
vanilloid derivatives belonging to the capsaicinoid (Winter et al.,
1993
), resiniferanoid (Ács et al., 1995
, 1996
; Walpole et al.,
1996
), unsaturated dialdehyde (Szallasi et al., 1996
, 1998
), and
triprenyl phenol (Szallasi et al., 1999a
) classes revealed that these
compounds have dissimilar potencies for receptor binding and inducing
45Ca2+-uptake,
respectively, in intact rat DRG neurons. The mechanistic basis for
these differences has not been defined; however, the distinct rank
order of vanilloid potencies for binding versus calcium uptake raised
the interesting possibility that these responses might, in fact, detect
two separate classes of vanilloid receptors. For example, RTX had been
found to bind to intact rat DRG neurons with an affinity of 40 pM but
only evoked calcium uptake in these cells with a 25-fold lower potency
(Ács et al., 1996
). Capsaicin showed the opposite behavior: it
was more potent for inducing calcium uptake (270 nM) than for
inhibiting RTX binding (3 µM) (Ács et al., 1996
). A vanilloid
receptor termed VR1 was recently cloned from a rat DRG cDNA library
(Caterina et al., 1997
). Therefore, the present study was designed to
address two questions of great importance. First, we examined whether
the cloned VR1 could bind RTX and, if so, whether it resembled the
specific RTX binding site described on DRG neurons. Second, we studied
whether or not VR1-transfected mammalian cells can mimic the distinct
affinities of selected vanilloids for receptor binding and calcium
response in DRG neurons.
C-type vanilloid receptors were believed to mediate calcium uptake in
sensory neurons, implying that these receptors were ion channels.
Because RTX did not evoke any detectable calcium uptake at low
concentrations, at which it labeled specific binding sites in DRG
neurons (Ács et al., 1997
), it was suggested that R-type
vanilloid receptors may not be ionotropic (Bíró et al., 1997
). Our clear finding is that VR1-transfected HEK293 or CHO cells
bind vanilloids with parameters very similar to those determined in rat
DRG neuron membranes in parallel experiments. Therefore, our conclusion
is that VR1 displays the structure-activity characteristics of the
putative R-type vanilloid receptor. Because VR1, a nonspecific cation
channel (Caterina et al., 1997
), should correspond to C-type vanilloid
receptors, our finding indicates that R- and C-type vanilloid
pharmacologies reflect different measures of the same target.
VR1 expression in various cellular systems shows discrepancies in
agonist potencies that may be indicative of receptor biology not yet
understood. For instance, Julius and coworkers (Caterina et al., 1997
;
Tominaga et al., 1998
) have described a 7-fold difference in
EC50 for capsaicin-evoked inward currents
mediated by VR1 in oocytes (710 nM) and in HEK293 cells (110 nM). The
latter value is in accord with the potency of capsaicin for mobilizing
calcium in HEK293/VR1 cells (82 nM; this study). We find, however, a
significant difference between capsaicin-evoked calcium mobilization in
CHO/VR1 cells (EC50 = 38 nM) and
capsaicin-induced
45Ca2+-uptake by DRG
neurons (270 nM). This difference in capsaicin potencies between
CHO/VR1 cells and DRG neurons was surprising because RTX showed similar
potencies (1.4 nM in CHO/VR1 cells and 1.0 nM in rat DRG neurons,
respectively) in the two assays. RTX, however, was 3-fold more potent
for mobilizing calcium in CHO/VR1 cells (EC50
= 1.4 nM) than in HEK293/VR1 cells (EC50
= 4.1 nM), although RTX was recognized by both VR1-transfected
cell types with similar binding affinities
(Kd values were 103 and 84 pM for CHO/VR1
and HEK293/VR1 cells, respectively). To a limited degree, the
discrepancies in agonist potencies observed for VR1-transfected cells
and DRG neurons may reflect methodological differences between the
calcium-activated fluorescence and the
45Ca2+-uptake assays.
However, methodology cannot account for all the differences in
vanilloid potencies, because capsaicin was found to be more active for
opening VR1 in HEK293 cells than in oocytes with use of a similar
(patch-clamping) procedure (Caterina et al., 1997
; Tominaga et al.,
1998
). Possible explanations include the existence of VR1 in multimeric
and/or spliced variant forms in neurons, leading to distortions in
vanilloid potencies in the calcium influx measurements. This is in
accord with the heterogeneity of vanilloid-gated conductances in
voltage-clamped neurons (Liu and Simon, 1996
; Petersen et al., 1996
).
The mechanistic basis for the discrepancies for vanilloids between
binding affinity and potency to mobilize calcium via VR1 also remains
to be established. It may be of relevance that RTX and capsaicin differ
not only in binding affinity and potency to evoke calcium uptake but
also in channel-gating kinetics (Winter et al., 1990
; Liu and Simon,
1996
). Upon challenge, capsaicin opens the channel rapidly whereas RTX,
a more bulky molecule, is delayed in action. Capsaicin-evoked inward
currents desensitize rapidly. By contrast, RTX-induced currents are
prolonged. This difference between capsaicin and RTX acting on native
vanilloid receptors expressed on intact neurons (Liu and Simon, 1996
)
is replicated in this study by using VR1-transfected mammalian cells. Consequently, this behavior relates to the biology of the receptor rather than to its neural environment. Interestingly, the time course
of the olvanil-evoked calcium response is similar to that by capsaicin
(this study), although olvanil mimics RTX rather than capsaicin in its
biological activities. For example, olvanil (Brand et al., 1990
), like
RTX (Szolcsányi et al., 1990
; Ács et al., 1997
), may
desensitize neurons without causing a detectable prior excitation.
At the methodological level, VR1-transfected mammalian cells represent
an attractive alternative to replace DRG neurons for pharmacological
characterization of vanilloid receptors. VR1 is gated not only by
vanilloids but also by noxious heat (>43°C) and protons (Tominaga et
al., 1998
). Slight acidification of the culture medium during cell
maintenance may decrease the temperature threshold of VR1 to 37°C
(Tominaga et al., 1998
). Thus, cells that continuously express VR1
eventually die due to the rising intracellular calcium levels. The use
of the pTet Off Regulator plasmid in the CHO/VR1 cells is important in
that it makes the long-term maintenance of VR1-tranfected cells
possible when tetracycline is included in the culture medium.
An interesting observation of this study is that the apparent potency
of capsazepine greatly depends on assay conditions; capsazepine is
almost 10-fold more potent to block capsaicin-induced calcium
mobilization in the presence of BSA. As yet, the mechanism(s) underlying this phenomenon is unclear. Possibilities include the coating of the air-water interphase with BSA and/or capsazepine binding
to this serum protein. Both mechanisms may provide a new equilibrium
for free capsazepine at a higher concentration. The inclusion/omission
of BSA (or any other factor that works in a similar fashion) may
account for many of the conflicting reports in the literature with
regard to apparent capsazepine potencies. For example, capsazepine was
reported to antagonize capsaicin responses in the isolated rat spinal
cord-tail preparation with an IC50 value of 254 nM (Dickenson and Dray, 1991
) but was found to block the
capsaicin-evoked contractions of the rat urinary bladder with an
IC50 of 5000 nM (Maggi et al., 1993
). Although in
this study the presence or absence of BSA had no effect on the potency
of any other vanilloid tested in the calcium mobilization assay,
capsazepine is not the only vanilloid whose apparent potency may be
enhanced by the inclusion of BSA. Some lipophilic phorboid vanilloids
appear to behave in a similar fashion (Szallasi et al., 1999b
).
Vanilloids are not only important tools to identify and study subsets
of primary sensory neurons (Holzer, 1991
) but have a clear therapeutic
potential as well (Maggi, 1992
; Szallasi and Blumberg, 1996
; Hautkappe
et al., 1998
). Capsaicin-containing creams are already
commercially available to relieve itch and pain. RTX is currently
undergoing clinical trials for the indication of urinary bladder
hyperreflexia with promising results; a single RTX treatment seems to
result in a long-lasting improvement in patients without producing the
barely tolerable initial pain that limits the clinical usefulness of
capsaicin (Cruz et al., 1997
; Lazzeri et al., 1998
). RTX, however, has
its own shortcomings. For example, it is difficult to obtain by
chemical synthesis and cannot be given p.o. Therefore, the
identification of simplified, orally active vanilloids is an ongoing
objective. As discussed above, RTX is associated with R-type
pharmacology (higher affinity for binding), whereas capsaicin is the
prototype of compounds following C-type pharmacology (higher potency
for calcium mobilization). Therefore, we conclude that the simultaneous
evaluation of compounds for binding versus calcium mobilization in
VR1-transfected mammalian cells could provide a rapid screen to
identify novel vanilloids that follow R- and C-type pharmacologies,
respectively. Biological evaluation of additional compounds selective
for one or the other response might be of interest.
| |
Acknowledgments |
|---|
We thank Michelle Arzubi and Aaron Walker for skillful technical assistance and Geoff White for helpful discussions.
| |
Footnotes |
|---|
Received February 17, 1999; Accepted May 26, 1999
1 Current address: Department of Pathology, Saint Louis University School of Medicine, 1402 South Grand Blvd., St. Louis, MO 63104.
Send reprint requests to: Dr. Arpad Szallasi, Department of Pathology, Saint Louis University School of Medicine, 1402 South Grand Blvd., St. Louis, MO 63104. E-mail: tszallasi{at}path.wustl.edu
| |
Abbreviations |
|---|
DRG, dorsal root ganglion; CHO/VR1 cells, Chinese hamster ovary cells transfected with VR1; HEK293/VR1 cells, human embryonic kidney cells transfected with VR1; RTX, resiniferatoxin; VR1, cloned rat vanilloid receptor subtype-1.
| |
References |
|---|
|
|
|---|
a sensory neurotoxin, in
Neurotoxins and Their Pharmacological Applications (Jenner P ed) pp 261-277,
Raven Press, New York.
1-acid glycoprotein (orosomucoid) as a major vanilloid-binding protein in serum.
J Pharmacol Exp Ther
262:
883-888This article has been cited by other articles:
![]() |
D. C. Broom, D. J. Matson, E. Bradshaw, M. E. Buck, R. Meade, S. Coombs, M. Matchett, K. K. Ford, W. Yu, J. Yuan, et al. Characterization of N-(Adamantan-1-ylmethyl)-5-[(3R-aminopyrrolidin-1-yl)methyl]-2-chloro-benzamide, a P2X7 Antagonist in Animal Models of Pain and Inflammation J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 620 - 633. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Xu, W. Tian, Y. Fu, T. T. Oyama, S. Anderson, and D. M. Cohen Functional effects of nonsynonymous polymorphisms in the human TRPV1 gene Am J Physiol Renal Physiol, December 1, 2007; 293(6): F1865 - F1876. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. R. Bianchi, R. El Kouhen, T. R. Neelands, C.-H. Lee, A. Gomtsyan, S. N. Raja, S. N. Vaidyanathan, B. Surber, H. A. McDonald, C. S. Surowy, et al. [3H]A-778317 [1-((R)-5-tert-Butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a Novel, Stereoselective, High-Affinity Antagonist Is a Useful Radioligand for the Human Transient Receptor Potential Vanilloid-1 (TRPV1) Receptor J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 285 - 293. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Endres-Becker, P. A. Heppenstall, S. A. Mousa, D. Labuz, A. Oksche, M. Schafer, C. Stein, and C. Zollner {micro}-Opioid Receptor Activation Modulates Transient Receptor Potential Vanilloid 1 (TRPV1) Currents in Sensory Neurons in A Model of Inflammatory Pain Mol. Pharmacol., January 1, 2007; 71(1): 12 - 18. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-R. Chen and H.-L. Pan Loss of TRPV1-Expressing Sensory Neurons Reduces Spinal {micro} Opioid Receptors But Paradoxically Potentiates Opioid Analgesia J Neurophysiol, May 1, 2006; 95(5): 3086 - 3096. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Lizanecz, Z. Bagi, E. T. Pasztor, Z. Papp, I. Edes, N. Kedei, P. M. Blumberg, and A. Toth Phosphorylation-Dependent Desensitization by Anandamide of Vanilloid Receptor-1 (TRPV1) Function in Rat Skeletal Muscle Arterioles and in Chinese Hamster Ovary Cells Expressing TRPV1 Mol. Pharmacol., March 1, 2006; 69(3): 1015 - 1023. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Milman, Y. Maor, S. Abu-Lafi, M. Horowitz, R. Gallily, S. Batkai, F.-M. Mo, L. Offertaler, P. Pacher, G. Kunos, et al. N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties PNAS, February 14, 2006; 103(7): 2428 - 2433. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Shimizu, T. Iida, N. Horiuchi, and M. J. Caterina 5-Iodoresiniferatoxin Evokes Hypothermia in Mice and Is a Partial Transient Receptor Potential Vanilloid 1 Agonist in Vitro J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1378 - 1385. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang, N. Kedei, M. Wang, Q. J. Wang, A. R. Huppler, A. Toth, R. Tran, and P. M. Blumberg Interaction between Protein Kinase C{micro} and the Vanilloid Receptor Type 1 J. Biol. Chem., December 17, 2004; 279(51): 53674 - 53682. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. R. Gavva, L. Klionsky, Y. Qu, L. Shi, R. Tamir, S. Edenson, T. J. Zhang, V. N. Viswanadhan, A. Toth, L. V. Pearce, et al. Molecular Determinants of Vanilloid Sensitivity in TRPV1 J. Biol. Chem., May 7, 2004; 279(19): 20283 - 20295. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Puntambekar, J. Van Buren, M. Raisinghani, L. S. Premkumar, and V. Ramkumar Direct Interaction of Adenosine with the TRPV1 Channel Protein J. Neurosci., April 7, 2004; 24(14): 3663 - 3671. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Jung, J. S. Shin, S.-Y. Lee, S. W. Hwang, J. Koo, H. Cho, and U. Oh Phosphorylation of Vanilloid Receptor 1 by Ca2+/Calmodulin-dependent Kinase II Regulates Its Vanilloid Binding J. Biol. Chem., February 20, 2004; 279(8): 7048 - 7054. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Toth, P. M. Blumberg, Z. Chen, and A. P. Kozikowski Design of a High-Affinity Competitive Antagonist of the Vanilloid Receptor Selective for the Calcium Entry-Linked Receptor Population Mol. Pharmacol., February 1, 2004; 65(2): 282 - 291. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang, A. Toth, R. Tran, T. Szabo, J. D. Welter, P. M. Blumberg, J. Lee, S.-U. Kang, J.-O. Lim, and J. Lee High-Affinity Partial Agonists of the Vanilloid Receptor Mol. Pharmacol., August 1, 2003; 64(2): 325 - 333. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Valenzano, E. R. Grant, G. Wu, M. Hachicha, L. Schmid, L. Tafesse, Q. Sun, Y. Rotshteyn, J. Francis, J. Limberis, et al. N-(4-Tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: I. In Vitro Characterization and Pharmacokinetic Properties J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 377 - 386. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Reilly, J. L. Taylor, D. L. Lanza, B. A. Carr, D. J. Crouch, and G. S. Yost Capsaicinoids Cause Inflammation and Epithelial Cell Death through Activation of Vanilloid Receptors Toxicol. Sci., May 1, 2003; 73(1): 170 - 181. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Southall, T. Li, L. S. Gharibova, Y. Pei, G. D. Nicol, and J. B. Travers Activation of Epidermal Vanilloid Receptor-1 Induces Release of Proinflammatory Mediators in Human Keratinocytes J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 217 - 222. [Abstract] [Full Text] [PDF] |
||||
![]() |
|